Low-Dose Digoxin as a Fifth Pillar in Contemporary Heart Failure Management

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  JAMA. https://doi.org/10.1001/jama.2026.7886 
Dr. Kevin Damman et al.

Points

Cardiologists at UMCG conducted a major study involving 1,000 heart failure patients to determine if low-dose digoxin provides additional benefits when added to the standard four-drug treatment regimen.
The primary study found that digoxin reduced cardiovascular deaths and worsening heart failure by 19 percent while a subsequent meta-analysis confirmed a 25 percent reduction in hospital admissions.
Low-dose digoxin proved to be a safe and inexpensive addition to the contemporary therapeutic bundle known as the Fantastic Four without increasing the risk of adverse cardiovascular events.
Researchers anticipate these findings will prompt a significant update to international heart failure guidelines to allow broader patient access to this effective and affordable digitalis glycoside medication.
Reducing recurrent hospitalizations is a critical priority for the estimated 500,000 heart failure patients in the Netherlands as the prevalence of the condition continues to rise annually.

Summary

This study evaluated the clinical utility of low-dose digoxin as an adjunct to the contemporary “Fantastic Four” pharmacological regimen for heart failure. Researchers from University Medical Center Groningen (UMCG) conducted a randomized controlled trial involving 1,000 Dutch patients across 43 centers. The primary composite endpoint was defined as the time to cardiovascular death or the first worsening heart failure event. Participants were randomized to receive either a low-dose digoxin or a placebo over a mean follow-up period of three years to assess the drug’s impact on disease progression and mortality.

Initial findings from the cohort indicated that digoxin reduced cardiovascular mortality and worsening heart failure events by 19%, although this specific result did not initially reach the threshold for statistical significance. However, a subsequent network meta-analysis integrating these results with data from two previous large-scale studies confirmed a robust therapeutic benefit. The comprehensive analysis demonstrated that digoxin provides significant added value in modern heart failure management, primarily driven by a substantial and statistically significant average reduction of 25% in heart failure-related hospital admissions.

Furthermore, the research established that a low-dose digoxin protocol is both safe and easily tolerated when administered alongside standard foundational therapies. Secondary outcomes, including all-cause mortality and individual components of the composite endpoint, suggest that this inexpensive digitalis glycoside remains a viable fifth pillar for optimizing patient outcomes. Given these findings, the investigators anticipate a shift in clinical guidelines, advocating for broader access to digoxin to mitigate the socioeconomic and physiological burdens of recurrent hospitalizations in the growing heart failure population.

Link to the article: https://jamanetwork.com/journals/jama/fullarticle/2848972

References

Damman, K., Van Veldhuisen, D. J., Bauersachs, J., Rienstra, M., Mosterd, A., Voors, A. A., Voordes, G. H. D., Bavendiek, U., & Van Der Meer, P. (2026). Efficacy and safety of digitalis glycosides in heart failure: A meta-analysis. JAMA. https://doi.org/10.1001/jama.2026.7886